Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin.
Currently, few antimalarial treatments exist that effectively kill liver-stage malaria parasites, which can lay dormant for months or years as in the case of Plasmodium vivax. Researchers from Kanazawa University have successfully demonstrated that administration of a baculovirus virion completely eliminates liver-stage parasites in a mouse model via BV-induced fast-acting innate immunity.
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.
A novel laboratory-synthesized molecule based in natural compounds found in marine gliding bacteria - known as marinoquinolines - is a strong candidate for the development of a new antimalarial drug.
Coupling free diagnostic tests for malaria with discounts on artemisinin combination therapy (ACT) when malaria is diagnosed can improve the rational use of ACTs and boost testing rates, according to a cluster-randomized trial published this week in PLOS Medicine by Wendy Prudhomme O’Meara of Duke University, USA, and colleagues.
Equal subsidies "surprisingly powerful," in promoting use of gold-standard medications, new study shows.
Research has revealed the shocking lack of access to essential medicines in India, despite thousands being approved in an attempt to generate wider availability.
Indiana University School of Medicine researchers have identified a way to block the ability of parasites that cause malaria to shield themselves against drug treatments in infected mice--a finding that could lead to the development of new approaches to combat this deadly disease in humans.
A new analysis of all relevant previously published clinical data shows how parasites causing malaria become resistant to a commonly used treatment for malaria in travellers.
The Global Health Innovative Technology Fund, a unique Japanese public-private partnership formed to battle infectious diseases around the globe, today announced US$16.7 million to support development of new compounds for fighting malaria and tuberculosis, a leishmaniasis vaccine and drug, and a treatment for a long-ignored flesh-eating infection.
The spread of a single multidrug resistant malaria parasite strain in Vietnam is cause for alarm say researchers.
Texas Biomedical Research Institute researchers, Dr. Tim Anderson and Dr. Ian Cheeseman, have partnered with researchers at the University of Notre Dame and the Center for Infectious Disease Research in Seattle to pursue studies in drug resistant malaria.
Artemisinin, a potent anti-malarial drug, has been widely hailed as a promising alternative cancer treatment. Scientists from the National University of Singapore recently showed that its anti-cancer properties could be enhanced by 10 folds when used in combination with Aminolaevulinic acid, a photosensitizer or a drug which, upon exposure to light, leads to generation of free radicals that can kill cells.
Compared to smallpox or typhoid, malaria is proving one of the most challenging human diseases to eradicate - and so remains a real and constant danger to nearly half the world's population.
The National Institutes of Health has renewed a major grant that funds a University of Washington-led research center to understand malaria in India.
Malaria is more common and severe in pregnant women, increasing their risk of miscarriage and other adverse outcomes. The adverse consequences of malaria in pregnancy require prompt, safe, and effective treatment.
When the standard malaria medications failed to help 18 critically ill patients, the attending physician in a Congo clinic acted under the "compassionate use" doctrine and prescribed a not-yet-approved malaria therapy made only from the dried leaves of the Artemisia annua plant.
Since the ancient times, mankind has used plants to treat diseases. An example is the plant Artemisia annua, used for over 2,000 years in traditional Chinese medicine to treat intermittent fevers.
Researchers at Cardiff University have devised a new way of creating a drug commonly used as the first line of defence against malaria around the world.
Malaria infections may soon be treated much more efficiently than they are at present. Researchers at the Universities of Bayreuth and Jerusalem have developed a novel drug release procedure for this purpose.